Evidence map›Paper›PMID 42260757›Full record

ReviewChinese medical journal2026

PI3K-Akt signaling network crosstalk in cerebral ischemia/reperfusion injury: Mechanisms and therapeutic implications.

Wenzhe Yang, Qian Yang, Zhihui Wang, Xu Zhao, Jingxuan Deng, Xinran Xia, Jinzheng Wang, Linhui Xia, Yanfang Wang, Fen Cui and 2 more

Abstract readReview
In one paragraph

Review in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenzhe YangCollege of Acupuncture and Massage, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
Qian YangCollege of Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
Zhihui WangCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
Xu ZhaoCollege of Health, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
Jingxuan DengCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
Xinran XiaCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355, China.
Jinzheng WangCollege of Clinical Medicine, Jining Medical University, Jining, Shandong 272067, China.
Linhui XiaCollege of Clinical Medicine, Jining Medical University, Jining, Shandong 272067, China.
Yanfang WangState Key Laboratory of Animal Nutrition, Institute of Animal Science, Chinese Academy of Agricultural Sciences, Beijing 100193, China.
Fen CuiBehavioral Medicine Education Institute, Jining Medical University, Jining, Shandong 272002, China.
Rubin TanDepartment of Physiology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan 646000, China.
Jinxiang YuanLin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining, Shandong 272067, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractCerebral ischemia (CI) is an acute central nervous system disorder resulting from the abrupt interruption of blood flow to brain tissue. The restoration of blood flow during treatment is frequently accompanied by cerebral ischemia/reperfusion (CI/R) injury, a secondary injury mechanism that substantially limits the overall efficacy of reperfusion therapy. The phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) signaling pathway, a central regulator of cell survival, proliferation, and stress response, has attracted growing interest for its role in CI and CI/R injury. During the early ischemic phase, PI3K-Akt activation in neurons and brain microvascular endothelial cells serves as a crucial endogenous protective mechanism, inhibiting apoptosis and maintaining energy metabolic homeostasis, thereby mitigating initial brain damage. As ischemia progresses, downregulation of this pathway in microglia and infiltrating macrophages can promote excessive release of proinflammatory factors, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), exacerbating local inflammation and tissue injury. In the reperfusion phase, reactivation of the PI3K-Akt pathway exerts multi-level neuroprotection: It counteracts neuronal apoptosis and oxidative stress, promotes angiogenesis and blood-brain barrier (BBB) repair in endothelial cells, and modulates neuroinflammation in glial cells. Importantly, the PI3K-Akt pathway does not function in isolation but engages in complex crosstalk with multiple signaling cascades, such as Wnt/β-catenin, nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1), and mammalian target of rapamycin (mTOR). Moreover, it shapes the immune microenvironment by fine-tuning the functions of immune cells, including regulatory T cells (Tregs). This intricate network dynamically governs the survival of the neurovascular unit by regulating mitochondrial function, oxidative stress, inflammation, and autophagy. This review systematically explores the dynamic changes, cell-specific functions, and interactive mechanisms of the PI3K-Akt pathway during CI and CI/R injury, and discusses its potential for precision treatment strategies and clinical translation.

Indexed as

Brain IschemiaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReperfusion InjuryAnimalsBlood-Brain BarrierHumansOxidative StressSignal TransductionPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAngiogenesisBlood–brain barrier injuryCerebral ischemia/reperfusion injuryInflammationNetwork crosstalkOxidative stressPI3K–Akt pathwayTherapeutic strategies

Identifiers

PMID42260757
PMCPMC13592988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.